Education
About Us
Working with TipRanks
Follow Us
Korro Bio (KRRO)
NASDAQ:KRRO
KRRO Analyst Ratings
Strong Buy
5 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
KRRO Stock 12 Month Forecast
Average Price Target
$100.50
▲(528.52% Upside)
| Highest Price Target$147.00 | Average Price Target$100.50 | Lowest Price Target$80.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Cantor Fitzgerald
$153→$147
Buy
819.32%
Upside
Reiterated
08/13/25
H.C. Wainwright
$100→$90
Buy
462.85%
Upside
Reiterated
08/13/25
RBC Capital
$85
Buy
431.58%
Upside
Reiterated
08/12/25
William Blair
―
Buy
―
Reiterated
08/12/25
Korro Bio (KRRO) Gets a Buy from William BlairWe note that unlike KRRO-110, this asset will use GalNAc conjugation for subcutaneous liver targeting. The company has also disclosed assets targeting the CNS. In addition, Korro has made advancements in its collaboration with Novo Nordisk (NVO $49.78) to develop up to two RNA editing assets using its OPERA platform to address cardiometabolic diseases.
BMO Capital
$80
Buy
400.31%
Upside
Reiterated
08/12/25
Piper Sandler
$180
Buy
1025.70%
Upside
Reiterated
05/08/25
Chardan Capital
$25
Buy
56.35%
Upside
Initiated
04/16/25
Oppenheimer
$155
Buy
869.36%
Upside
Initiated
01/10/25
JonesTrading
$130
Buy
713.01%
Upside
Initiated
11/17/24
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Cantor Fitzgerald
$153→$147
Buy
819.32%
Upside
Reiterated
08/13/25
H.C. Wainwright
$100→$90
Buy
462.85%
Upside
Reiterated
08/13/25
RBC Capital
$85
Buy
431.58%
Upside
Reiterated
08/12/25
William Blair
―
Buy
―
Reiterated
08/12/25
Korro Bio (KRRO) Gets a Buy from William BlairWe note that unlike KRRO-110, this asset will use GalNAc conjugation for subcutaneous liver targeting. The company has also disclosed assets targeting the CNS. In addition, Korro has made advancements in its collaboration with Novo Nordisk (NVO $49.78) to develop up to two RNA editing assets using its OPERA platform to address cardiometabolic diseases.
BMO Capital
$80
Buy
400.31%
Upside
Reiterated
08/12/25
Piper Sandler
$180
Buy
1025.70%
Upside
Reiterated
05/08/25
Chardan Capital
$25
Buy
56.35%
Upside
Initiated
04/16/25
Oppenheimer
$155
Buy
869.36%
Upside
Initiated
01/10/25
JonesTrading
$130
Buy
713.01%
Upside
Initiated
11/17/24
Best Analysts Covering Korro Bio
1 Month
xxx
Success Rate
6/14 ratings generated profit
Average Return
+0.43%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 42.86% of your transactions generating a profit, with an average return of +0.43% per trade.
3 Months
xxx
Success Rate
6/12 ratings generated profit
Average Return
-18.18%
reiterated a xxx
rating 2 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of -18.18% per trade.
1 Year
Success Rate
2/14 ratings generated profit
Average Return
-41.60%
reiterated a buy rating 3 months ago
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 14.29% of your transactions generating a profit, with an average return of -41.60% per trade.
2 Years
xxx
Success Rate
1/12 ratings generated profit
Average Return
-52.92%
reiterated a xxx
rating 2 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 8.33% of your transactions generating a profit, with an average return of -52.92% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
KRRO Analyst Recommendation Trends
Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
10
11
8
7
5
Buy
1
2
1
1
1
Hold
5
5
4
0
0
Sell
1
0
0
0
0
Strong Sell
0
0
0
0
0
total
17
18
13
8
6
Each month's total comprises the sum of three months' worth of ratings.
KRRO Financial Forecast
KRRO Stock Forecast FAQ
What is KRRO’s average 12-month price target, according to analysts?
Based on analyst ratings, Korro Bio’s 12-month average price target is 100.50.
What is KRRO’s upside potential, based on the analysts’ average price target?
Korro Bio has 528.52% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is KRRO a Buy, Sell or Hold?
Korro Bio has a consensus rating of Strong Buy which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.
What is Korro Bio’s price target?
The average price target for Korro Bio is 100.50. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $147.00 ,the lowest forecast is $80.00. The average price target represents 528.52% Increase from the current price of $15.99.
The highest analyst price target is $147.00 ,the lowest forecast is $80.00. The average price target represents 528.52% Increase from the current price of $15.99.
What do analysts say about Korro Bio?
Korro Bio’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
How can I buy shares of KRRO?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.